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Abstract
Background: Dupuytren’s disease is a progressive fibroproliferative disorder which can result in fixed flexion
contractures of digits and impaired hand function. Standard treatment involves surgical release or excision
followed by post-operative hand therapy and splinting, however the evidence supporting night splinting is of low
quality and equivocal.
Methods: A multi-centre, pragmatic, open, randomised controlled trial was conducted to evaluate the effect of
night splinting on self-reported function, finger extension and satisfaction in patients undergoing fasciectomy or
dermofasciectomy. 154 patients from 5 regional hospitals were randomised after surgery to receive hand therapy
only (n = 77) or hand therapy with night-splinting (n = 77). Primary outcome was self-reported function using the
Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. Secondary outcomes were finger range of
motion and patient satisfaction. Primary analysis was by intention to treat.
Results: 148 (96%) patients completed follow-up at 12 months. No statistically significant differences were
observed on the DASH questionnaire (0-100 scale: adjusted mean diff. 0.66, 95%CI - 2.79 to 4.11, p = 0.703), total
extension deficit of operated digits (degrees: adjusted mean diff 5.11, 95%CI -2.33 to 12.55, p = 0.172) or patient
satisfaction (0-10 numerical rating scale: adjusted mean diff -0.35, 95%CI -1.04 to 0.34, p = 0.315) at 1 year post
surgery. Similarly, in a secondary per protocol analysis no statistically significant differences were observed between
the groups in any of the outcomes.
Conclusions: No differences were observed in self-reported upper limb disability or active range of motion
between a group of patients who were all routinely splinted after surgery and a group of patients receiving hand
therapy and only splinted if and when contractures occurred. Given the added expense of therapists’ time,
thermoplastic materials and the potential inconvenience to patients having to wear a device, the routine addition
of night-time splinting for all patients after fasciectomy or dermofasciectomy is not recommended except where
extension deficits reoccur.
Trial registration: The trial was registered as an International Standard Randomised Controlled Trial
ISRCTN57079614
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Dupuytren’s disease (DD) is a disabling hand condition
that is thought to affect more than 2 million people in
the UK [1]. Standard surgical treatment includes division
of the cords (fasciotomy) or excision (partial or total fas-
ciectomy) [1]. Long term recurrence may be reduced by
excision of cords/nodules with the overlying skin and full
thickness skin grafting (dermofasciectomy) [2].
Less invasive percutaneous needle fasciotomy [3] and
injectable collagenase (’chemical knife’)[ 4 ]a r ea l t e r n a -
tive outpatient delivered procedures resulting in good
short-term contracture release, however fasciotomy is
also associated with a much higher recurrence rate com-
pared to limited fasciectomy [5].
Surgical excision (fasciectomy) of the diseased cords
continues to be a widely used treatment option aimed at
correcting the digital contractures and to improve hand
function. Rehabilitation post surgery by hand therapists
is recommended [6] to control scar formation, prevent
secondary complications, and to restore movement and
hand function. The use of thermoplastic extension
splints worn at night and/or daytime is advocated by
many as part of the post-operative rehabilitation [6,7].
However a systematic review [8] concluded that there is
conflicting evidence on the effectiveness of post-opera-
tive splinting for Dupuytren’s disease with both positive
and negative results reported.
The paucity of research to date is reflected by the
inconsistent use of splinting in clinical practice. A sur-
vey of 573 orthopaedic consultants in the UK showed
that 33% used splinting most or all of the time [9] yet
another survey of 141 surgeons found that 84% advo-
cated night splinting [10].
Finally, splints may be inconvenient for patients to
wear and the materials, therapists’ time and skill
required to fabricate these custom-made devices are an
added expense to health care providers.
The aim of this study was to compare the effect of
post-operative static night splinting in addition to hand
therapy with hand therapy only on patient reported
upper extremity symptoms and disability, composite
active digital range of motion, patient satisfaction and
recurrence of contracture at one year.
Methods
Patients and Setting
We conducted an open, pragmatic, multi-centre, rando-
mised controlled trial of night-time static splinting worn
for 6 months after contracture release to assess the
effect on self-reported upper extremity function, active
range of movement in all digits and patient satisfaction
at 12 months follow-up.
Between October 2007 and January 2009 patients
referred with Dupuytren’s disease affecting one or more
digits of either hand and requiring fasciectomy or der-
mofasciectomy were invited to participate. Patients had
to be over 18 years of age and competent to give fully
informed written consent. Patients presenting with con-
tracture of the thumb or first web-space only were
excluded.
Identifying eligible patients was conducted in five
National Health Service (NHS) Hospital Trusts in East
Anglia involving a total of 16 operating surgeons. The
surgery and all post-operative interventions were deliv-
ered within these five secondary care centres. Data col-
lection at baseline and all follow-up assessments for the
trial were undertaken in the patients’ own homes by
two trained research associates.
The protocol was approved by the Cambridgeshire 2
Research Ethics Committee (REC 07/Q0108/120) in July
2007 and the Research Governance and Ethics Commit-
tee of each participating hospital. All patients gave fully
informed written consent.
Randomisation
Patients were randomised after surgical release at their
first post-operative appointment by the treating hand
therapist (within 2 weeks after surgery and following
removal of sutures). Randomisation was stratified by
centre (five centres) and by surgical procedure (fasciect-
omy or dermofasciectomy) in block lengths of 4. The
allocation sequence was generated and administered
independently through a central telephone randomisa-
tion service at the Clinical Trials Unit, University of
East Anglia. Neither the treating therapists nor the
patients were blinded to treatment allocation.
Interventions
The intervention being studied in this trial was static
splinting worn at night-time for 6 months after surgical
release in addition to usual hand therapy. As this was a
pragmatic trial we did not attempt to standardise surgi-
cal procedure. Surgeons were allowed to use their pre-
ferred surgical techniques tailored to the severity and
extent of the contracture. Hand therapy could not be
standardised as it is a complex intervention using multi-
ple modalities to treat a wide range of post-operative
p r o b l e m sa n dh a st ob et a i l o r e dt ot h ep a t i e n t ’s needs.
In order to collect data on the range of modalities and
treatments used by hand therapists, such as oedema
control, exercises or advice, hand therapists were asked
to complete a treatment reporting form at each session.
This was also used to record post-operative complica-
tions and reasons for treatment deviation from protocol.
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Patients randomised to the splint group were provided
with a custom-made thermoplastic splint fabricated by
the treating hand therapist. The splint was designed to
accommodate the operated rays of the hand with the
metacarpophalangeal joint (MCPJ) and/or proximal
interphalangeal joint (PIPJ) held in maximum extension
without causing any tension to the wound. After a
further 3 weeks when the wound has healed and scar
tissue begins to mature the splint could be remoulded
to achieve a greater extension force designed to prevent
any loss of extension from surgical scar contracting.
Patients were instructed to wear the splint at night
only and were given a splint diary in which they
recorded weekly how many nights out of 7 they had
actually worn the splint and any reasons why the splint
was not worn.
No splint group
The experimental treatment involved providing usual
hand therapy only. However, it was deemed unethical to
withhold the application of a splint in patients who
developed contractures and which did not respond to
hand therapy only. Clinical staff from all five centres
were consulted prior to the trial to devise criteria for
‘per protocol’ deviations for patients allocated to the no-
splint group in the event that they experience a rapid
and substantial loss of finger extension. At the first
hand therapy visit and following randomisation active
range of movement of MCPJ and PIPJ was measured by
the hand therapist with a goniometer and recorded. At
the 2
nd visit (normally 1 week later) this range of
motion was re-measured and if the patient had a net
loss of 15° or more at the PIPJ and/or a net loss of 20°
or more at the MCPJ of the operated fingers, they were
then given a splint and splint diary. The dates and rea-
sons for these protocol deviations were recorded by the
hand therapists and the trial coordinator was notified.
Any patients allocated to the no-splint group who were
given a splint for any other reasons such as surgeon
request were recorded as protocol violations.
Outcome assessment
The primary outcome measure was self-reported upper
extremity function using the 30-item Disabilities of the
Arm, Shoulder and Hand (DASH) questionnaire. The
DASH is a validated measure of symptoms and physical
function for patients with a wide range of musculoskele-
tal disorders of the upper extremity and has been exten-
sively used in reporting the outcome of surgery for DD
before [11-13]. The questionnaire was mailed to patients
for self-completion prior to the research associates’ visit
at which secondary assessments were taken.
Secondary outcomes were active range of motion of the
MCPJ, PIPJ and distal interphalangeal joint (DIPJ) of
operated digits and patient satisfaction. Range of motion
was assessed with a Rolyan (Sammons Preston, USA) fin-
ger goniometer and following a standardised protocol
[14]. Training was given prior to the trial and both
research associates undertook comparative assessments
at regular intervals. Individual joint movement of full
active flexion and extension was summed for each oper-
ated finger and averaged to give a total active extension
(TAE) and total active flexion (TAF). Any hyperextension
of a joint was recorded but converted to zero for the ana-
lysis to prevent underestimation of extension deficit.
Primary and secondary outcomes were assessed prior
to surgery, and at 3, 6 and 12 months after surgery.
Patient satisfaction was assessed only at 6 and 12
months by asking the patient to rate their satisfaction
with the outcome using an 11-point verbal rating scale
where 0 indicates complete dissatisfaction and 10 com-
plete satisfaction. The original protocol also indicated
recurrence at 1 year as a secondary outcome, however
this was abandoned due to the inherent difficulties of
d i s t i n g u i s h i n gat r u er e c u r r e n c ef r o mar e s i d u a ls c a r
contracture, the lack of agreed definition of recurrence
[15] and the subjectivity in visually inspecting and pal-
pating the hand.
Statistical approaches
Sample size
Using the DASH as the primary outcome measure,
w h e r ead i f f e r e n c eo f1 5p o i n t si sc o n s i d e r e dt ob ea
minimal important change (MIC) [16] and using a
between-group standard deviation of 22 points [17] a
total of 51 patients would be needed in each group for a
power of 90%. Allowing for a 20% loss to follow-up a
total of 128 randomised patients was aimed for.
Analysis methods
Baseline demographic and clinical characteristics were
compared between groups using descriptive statistics to
assess any potential disparities between groups.
The primary outcome, the DASH score, was found to
be very right-skewed and therefore a logarithmic trans-
formation was applied to produce a more symmetric
distribution, assumed to be Normal. A general linear
model was used to formally analyze the between group
mean difference adjusting for the baseline DASH score,
recruiting hospital and type of surgery (the latter two
variables were used to stratify randomisation).
Range of motion, that is total active flexion (TAF) and
total active extension (TAE) both appeared to follow a
Normal distribution. These were also analysed using a
general linear model with adjustment for baseline TAF
or TAE values, recruiting hospital and type of surgery.
Similarly, at 6 and 12 months, the patient satisfaction
score was analysed using a general linear model with
adjustment for recruiting hospital and type of surgery.
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apy sessions with adjustment for recruiting hospital and
surgery type. Similarly, a Logistic regression model was
used to analyse the use of a dynamic splint again with
adjustment for recruiting hospital and surgery type.
As appropriate to pragmatic trials an intention-to-treat
approach was used as the primary analysis strategy in
which all patients were analysed according to their initial
group allocation. However, no data imputation was used
for missing follow-up data as these were very few.
A secondary per-protocol analysis was conducted
comprising those individuals that adhered to the treat-
ment protocol. In the splint group, adherence was
defined a priori as wearing the splint for at least 50% of
nights in the first three months after surgery. In the no-
splint group the per protocol analysis included those
individuals who did not use a splint or were managed as
‘per protocol’ and given a splint once their extension
loss exceeded the criterion agreed by the trial manage-
ment group.
For the intention-to-treat analysis the statistician (LS)
was sub-group blind.
The trial was registered as an International Standard
Randomised Controlled Trial, number ISRCTN57079614
on http://www.controlled-trials.com. The trial was
funded by Action Medical Research Charity, UK.
Results
Between October 2007 and January 2009 218 patients
were referred as eligible and invited to participate. 46
patients declined, one patient withdrew and one patient
died. A further 16 patients were excluded because either
their surgery had been cancelled or postponed (n = 8),
they were mistakenly referred after surgery (n = 6), one
patient could not be contacted and one patient was not
referred to hand therapy (n = 1).
A total of 154 patients were thus enrolled into the
trial from December 2007 to January 2009 and ran-
domly allocated to either trial arm (see Figure 1). Fol-
low-up continued until January 2010 and six patients
were lost to follow-up (4%). Of the 77 patients allocated
to receive a splint, one patient refused the splint and
was also lost to follow-up. In the no-splint group 69 of
the 77 patients received the allocated intervention of
hand therapy only. There were eight protocol violations
in the no-splint group: one patient was given a splint by
mistake prior to randomisation and seven patients were
given a splint immediately at their first hand therapy
appointment either due to surgeon request or because
the patient already presented with a loss of extension.
13 patients allocated to the no - s p l i n tg r o u p( 1 7 % )w e n t
on to develop a contracture of the PIPJ which exceeded
the agreed threshold and were subsequently given a
splint as per protocol.
The baseline demographic and clinical characteristics
for the two groups are given in Table 1. Both groups
were similar with regards to clinical characteristics
except for the proportion of patients who had one or
more digits operated with a slightly larger proportion of
multiple digit involvement in the no-splint group. A fas-
ciectomy was the most common procedure with only 16
patients receiving a dermofasciectomy.
Table 2 presents the results of the ITT analysis for
primary and secondary outcomes at 3, 6 and 12 month
by treatment group and the adjusted mean difference
with 95% confidence interval. There were no statistically
significant differences at 12 months between the two
groups in DASH score (0.66, -2.79 to 4.11, p = 0.703),
degrees of total active flexion of operated digits (-2.02,
-7.89 to 3.85, p = 0.493), degrees of total active exten-
sion deficit of operated digits (5.11, 2.33 to -12.55, p =
0.172). Both groups were satisfied with the outcome at
12 months (mean 8.5 splint group and 8.9, no-splint
group) and did not differ significantly (-0.35, -1.04 to
0.34, p = 0.315). Similarly, no significant differences
were found at 3 or 6 months.
The mean number of therapy sessions was 5.1 (SD
2 . 5 )i nt h es p l i n tg r o u pa n d5 . 6( S D3 . 5 )i nt h en o
-splint group. There were no significant differences in
number of therapy sessions between the two groups
(adjusted odds ratio: 0.93, 0.81 to 1.07, p = 0.305). The
use of subsequent dynamic daytime splints for residual
PIPJ contractures was similar for both groups (13
patients in splint group and 14 in no-splint group) and
was not statistically significant (adjusted odds ratio: 0.91,
0.35 to 2.36, p = 0.839).
A secondary per protocol analysis was conducted on
all those patients in whom the treatment protocol was
adhered to. This included those patients allocated to the
s p l i n tg r o u pa n dw o r et h es p l i n tf o ra tl e a s t5 0 %o f
nights in the first 3 months. In those allocated to the
no-splint it includes the 13 patients given a splint due
to ensuring contracture. Table 3 gives the results for the
per protocol analysis for primary and secondary out-
comes at 3 months, 6 months and 12 months. No statis-
tically significant differences were found on any of the
outcomes and at any time points.
Mean adherence to splint wear in the first 3 months
was 74.6% of nights (SD = 29.4%) and only 12 patients
did not meet the adherence criterion (splint worn ≥50%
of night for first 3 months). Reasons for non-adherence
or discontinuing splint wear were documented in the
splint diary. The most commonly cited reason (n = 12)
was the patient no longer perceiving any benefit from
wearing the splint, other reasons were: causing hand
stiffness, causing discomfort or pain, sleep disturbance,
advised to discontinue by surgeon, ill fitting or causing a
rash.
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This pragmatic trial has shown that the policy of using
routine night-time static splints in addition to usual
post-operative hand therapy does not offer any addi-
tional benefit in terms of self-reported hand function
and disability, active composite range of flexion or
extension or patient satisfaction. Both groups improved
over the 12 months follow-up period in their DASH
score. However any between group differences were not
statistically significant and the 95% confidence intervals
included values of 5 points or less which are well below
the threshold for a minimal important change in DASH.
As surgery is primarily aimed at releasing contracted
tissues and splints designed to maintain this extension,
total extension deficit is an important clinical measure
of change and a more proximate outcome. However the
ITT analysis found no statistically significant differences
between the two groups on either active extension or
flexion.
A potential weakness of the trial is that the primary
outcome measure was patient-reported and participants
could not be blinded. Secondary outcomes were col-
lected by the research associates who were also not
blinded, although they were independent of the clinical
staff delivering the interventions. The lack of blinding
could introduce a bias but this bias is more likely to be
in favour of splinting (i.e. those patients with an active
intervention more likely to report favourable results).
The fact that the trial did not find evidence in support
of splinting would mitigate against the possible
Referred as eligible by 
surgeons (n=218)
Excluded  (n=64)
i   Declined to participate (n=46)
i   excluded for other reasons (n=18)
1° outcome analysed at 3 months (n=76)
Lost to follow- u p( n = 1)
reasons: not contactable (n=1)
Allocated to splint group (n=77)
i Received allocated intervention (n=76) 
i Did not receive allocated intervention 
reasons: declined to wear splint  (n=1) 
1° outcome analysed at 3 months  (n=76)
Lost to follow-up (n=1)
reasons: ill health (n=1)
Allocated to non-splint group (n=77)
i Received allocated intervention (n=69) 
i Did not receive allocated intervention (n=8)
reasons: mistakenly given splint prior to 
randomisation (n=1); requested by 
surgeon (n=7)
13 patients developed contractures and were 
splinted as ‘per protocol’
Allocation 
6 months 
follow-up 
3 months 
follow-up 
Randomized (n=154)
Enrollment 
1° outcome analysed at 6 months (n=75)
Lost to follow- u p( n = 2)
reasons: not contactable (n=2)
1° outcome analysed at 6 months (n=76)
Lost to follow-up (n= 1)
reasons:  working abroad (n=1)
12 months 
follow-up 
1° outcome analysed at 12 months  (n=71)
Lost to follow- u p( n = 4)
reasons: died (n=1), hospitalised (n=1),
not contactable (n=2)
Missing data (n=2)
reason: DASH not returned despite    
reminders 
1° outcome analysed at 12 months  (n= 75)
Lost to follow-up (n=2)         
reasons: ill health (n=1), working abroad
(n=1)
Figure 1 CONSORT flowchart for SCoRD trial.
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tations to have a better outcome from splinting.
Our trial exceeded the required sample size for 90%
power, had a very high follow-up rate (96%) and even in
the secondary per protocol analysis the sample size still
exceeds 51 in each group, therefore the possibility of a
Type II error remains low, and yet the confidence
intervals exclude the minimally important difference for
the DASH.
There are several possible explanations for our results.
The primary outcome measure is a well-validated out-
come measure for upper limb function and disability.
However, DASH is a region-specific upper extremity
measure and not disease-specific. It may therefore lack
sensitivity to change in patients with Dupuytren’sc o n -
tracture. A clinically important change of 15 points as a
criterion is a large effect size especially when consider-
ing that the baseline mean score prior to surgery was
only 16 points, thus indicating minimal disability. Range
of movement of digital joints could be argued as a more
proximate and objective indicator of contracture severity
yet the differences between groups were also non-signif-
icant with small and narrow confidence intervals con-
firming that a splint does not offer any additional
benefit in terms of active extension or flexion of affected
digits.
A second possible reason for a lack of difference could
be dilution bias especially through non-adherence in the
splint group. Patients were asked to complete a weekly
splint diary, however overall mean adherence with splint
wear was high and only 12 patients in the splint group
were deemed as non-adherent (15.6%) at 3 months. The
results of the per protocol analysis which includes only
those who met the adherence criterion of splint wear
for ≥50% differences were still non-significant for all pri-
mary and secondary outcomes indicating that even
when the splint is worn or adhered to a lack of effect is
still evident. One weakness is that these adherence rates
relied on patient completed diaries. Whilst the diaries
were collected by research associates (not the treating
therapists or surgeon) and therefore encouraged patients
to be honest, independent verification of actual splint
wear was not possible.
A third plausible reason for the lack of effect could be
that the amount of tension provided through a static
night splint is not sufficient to remodel scar tissue. In a
study investigating full time casting in patients with an
orthopaedic injury improvement in PIP flexion contrac-
ture was related to the total time that the cast was worn
with greater extension achieved the longer the cast was
worn [18]. However it is unknown if the same principle
applies to an intermittent application of force such as
the use of a night splint only in post-operative Dupuyt-
ren’s disease.
The use of composite joint motion, that is adding
MCPJ, PIPJ and DIPJ range, is a potential limitation,
however separate analysis by joint means multiple
hypotheses tests and increases the risk of a Type I error.
It is also widely acknowledged that correction of PIPJ
contractures presents a greater challenge than in
patients with MCPJ involvement only. The trial was not
Table 1 Baseline demographic and clinical characteristics
Splint
group
No splint
group
N=7 7 N=7 7
Centre Cambridge 13 (17%) 13 (17%)
Ipswich 17 (22%) 18 (23%)
Norwich 30 (39%) 29 (38%)
Peterborough 5 (6%) 4 (5%)
West Suffolk 12 (16%) 13 (17%)
Age Mean (SD) 67.2 (10.0) 67.5 (9.2)
Sex Ratio male: female 61:16 59:18
Occupation Working 24 (31%) 29 (38%)
Seeking Work 1 (1%) 0
Retired/Not working 52 (68%) 48 (62%)
Surgery Type Dermofasciectomy 7 (9%) 9 (12%)
Fasciectomy 70 (91%) 68 (88%)
Operated Digit Index 5 (7%) 3 (4%)
Long 7 (9%) 16 (21%)
Ring 37 (49%) 26 (34%)
Small 56 (74%) 53 (69%)
No operated
rays
One 50 (66%) 60 (78%)
Two 23 (30%) 13(17%)
Three 3 (4%) 4 (5%)
Previous
Surgery
Yes 11 (14%) 12 (16%)
No 66 (86%) 65 (84%)
Woodruff Grade 2 (MCP only) 3 (4%) 7 (9%)
3 (MCP and PIP, single
digit)
42 (55%) 45 (58%)
4 (as 3 multiple digits) 32 (41%) 25 (33%)
Initial DASH
Score
Mean (SD) 16.4 (15.1) 15.4 (13.2)
Initial TAF* Mean (SD) 223.8 (20.9) 226.2 (15.0)
Initial TAE* Mean (SD) 50.7 (22.2) 51.1 (18.8)
TAF = total active flexion of MCPJ, PIPJ and DIPJ of operated digit(s) only
TAE = total active extension of MCPJ, PIP and DIPJ of operated digit(s) only
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results of such secondary analyses need to be inter-
preted with caution. We did conduct one such subgroup
analysis based on those patients who had surgery invol-
ving the PIPJ of the little finger (n = 109, 71% of total
sample). No statistically significant differences were
found between the groups on DASH or PIPJ flexion or
extension. These results concur with the the primary
analysis.
Our trial was pragmatic and its broad inclusion criteria,
the fact that it was a multi-centre trial across 5 hospitals
and involved 16 surgeons and around 26 therapists mean
that generalisability is good. The baseline clinical and
demographic characteristics of the whole cohort of 154
patients is typical of this patient group and although we
were unable to collect data on non-consenting patients
the fact that 73% of those invited consented, further sup-
ports the external validity of this trial. Furthermore we
have no evidence of selection bias in the method by
which surgeons screened patients for eligibility.
The interventions used in this pragmatic trial were
consistent with current practice within the 5 trusts and
we used practical criteria based on clinical reasoning to
agree protocol deviations, although the exact thresholds
for net loss of extension and therefore when to apply a
splint were arbitrary and could be reconsidered.
Our results are generalisable to patients managed sur-
gically by fasciectomy or dermofasciectomy, however
caution is needed in extrapolating these findings to
other surgical or less invasive procedures where the role
of post-operative hand therapy including splinting
remains largely unknown.
Conclusions
Contrary to the widespread belief in the value of post-
op night splinting for up to 6 months after fasciectomy
or dermofasciectomy we found no evidence of its short
or long-term effect. The policy of splinting all patients
referred for hand therapy immediately after fasciect-
omy or dermofasciectomy needs to be reconsidered.
Table 2 Intention-to-treat analysis for primary and secondary outcomes (mean and standard deviation)
Splint group No splint group Adjusted Difference 95% C.I. p-value
3-month DASH (0-100) 9.6 (12.8) 10.8 (12.5) -1.48 0.403
n = 76 n = 76 (-5.02 to 2.06)
LogDASH 1.74 (1.17) 1.87 (1.18) -0.16 0.372
n = 76 n = 76 (-0.50 to 0.19)
TAF (degrees) 213.0 (26.5) 217.6 (22.5) -3.49 0.326
n = 75 n = 76 (10.57 to -3.59)
TAE (degrees) -32.9 (19.6) -30.9 (20.7) 3.30 0.209
n = 75 n = 76 (1.93 to -8.53)
6-month DASH 7.9 (11.4) 7.1 (10.7) 0.20 0.890
n = 75 n = 76 (-2.72 to 3.12)
LogDASH 1.47 (1.21) 1.38 (1.21) 0.07 0.704
n = 75 n = 76 (-0.29 to 0.43)
TAF 220.6 (25.2) 225.8 (21.6) -4.16 0.199
n = 74 n = 76 (-10.6 to 2.29)
TAE -31.0 (23.3) -28.4 (21.1) 4.52 0.142
n = 74 n = 76 (-1.61 to 10.65)
Patient Satisfaction (0-10) 8.7 (1.89) 9.0 (1.23) -0.28 0.286
n = 75 n = 76 (-0.81 to 0.24)
12-month DASH 7.0 (14.6) 6.0 (9.2) 0.66 0.703
n = 71 n = 75 (-2.79 to 4.11)
LogDASH 1.24 (1.21) 1.23 (1.20) -0.02 0.914
n = 71 n = 75 (-0.38 to 0.34)
TAF 223.8 (25.7) 227.3 (19.5) -2.02 0.493
n = 72 n = 75 (-7.89 to 3.85)
TAE -32.9 (27.4) -29.6 (23.3) 5.11 0.172
n = 72 n = 75 (-2.33 to 12.55)
Patient Satisfaction 8.5 (2.33) 8.9 (1.79) -0.35 0.315
n = 73 n = 75 (-1.04 to 0.34)
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of splinting when adhered to for at least 50% of nights
in the first 3 months compar e dt oh a n dt h e r a p ya n d
splinting only when contractures occur. Patients
receiving post-operative hand therapy by a specialised
occupational therapist or physiotherapist had at least
as good an outcome as those given an additional night
splint. Only a small proportion (17%) of patients allo-
cated to hand therapy went on to develop contractures
of the PIPJ which exceeded the agreed threshold and
needed a splint. Given the added expense of therapists’
time, thermoplastic materials and the potential incon-
venience to patients having to wear a device the policy
of routine addition of night-time splinting after fas-
ciectomy or dermofasciectomy should no longer be
advocated but only where a loss of extension has
occurred, particularly if the loss is rapid and early in
the post-operative period.
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